Your browser doesn't support javascript.
loading
Pharmacokinetics of midazolam and its major metabolite 1-hydroxymidazolam in the ball python (Python regius) after intracardiac and intramuscular administrations.
Larouche, Cédric B; Johnson, Ron; Beaudry, Francis; Mosley, Craig; Gu, Yu; Zaman, Kristopher Afshaun; Beaufrère, Hugues; Dutton, Christopher.
Afiliação
  • Larouche CB; Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
  • Johnson R; Toronto Zoo, Toronto, Ontario, Canada.
  • Beaudry F; Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
  • Mosley C; Groupe de Recherche en Pharmacologie Animale du Québec (GREPAQ), Département de Biomédecine Vétérinaire, Faculté de Médecine Vétérinaire, Université de Montréal, Saint-Hyacinthe, Québec, Canada.
  • Gu Y; VCA Canada, 404 Veterinary Emergency and Referral Hospital, Newmarket, Ontario, Canada.
  • Zaman KA; Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
  • Beaufrère H; Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
  • Dutton C; Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
J Vet Pharmacol Ther ; 42(6): 722-731, 2019 Nov.
Article em En | MEDLINE | ID: mdl-31469454
Midazolam is a benzodiazepine with sedative, muscle relaxant, anxiolytic, and anticonvulsant effects. Twelve ball pythons (Python regius) were used in a parallel study evaluating the pharmacokinetics of 1 mg/kg midazolam following a single intracardiac (IC) or intramuscular (IM) administration. Blood was collected from a central venous catheter placed 7 days prior, or by cardiocentesis, at 15 time points starting just prior to and up to 72 hr after drug administration. Plasma concentrations of midazolam and 1-hydroxymidazolam were determined by the use of high-performance liquid chromatography tandem-mass spectrometry and pharmacokinetic parameters were estimated using noncompartmental analysis. The mean ± SD terminal half-lives of IC and IM midazolam were 12.04 ± 3.25 hr and 16.54 ± 7.10 hr, respectively. The area under the concentration-time curve extrapolated to infinity, clearance, and apparent volume of distribution in steady-state of IC midazolam were 19,112.3 ± 3,095.9 ng*hr/ml, 0.053 ± 0.008 L hr-1  kg-1 , and 0.865 ± 0.289 L/kg, respectively. The bioavailability of IM midazolam was estimated at 89%. Maximum plasma concentrations following an IM administration were reached 2.33 ± 0.98 hr and 24.00 ± 14.12 hr postinjection for midazolam and 1-hydroxymidazolam, respectively, and 22.33 ± 20.26 hr postinjection for 1-hydroxymidazolam following IC administration.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Midazolam / Boidae Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Midazolam / Boidae Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2019 Tipo de documento: Article